343 related articles for article (PubMed ID: 35203256)
1. Harnessing Natural Killer Cells in Non-Small Cell Lung Cancer.
Russell É; Conroy MJ; Barr MP
Cells; 2022 Feb; 11(4):. PubMed ID: 35203256
[TBL] [Abstract][Full Text] [Related]
2. A tri-specific killer engager against mesothelin targets NK cells towards lung cancer.
Kennedy PR; Vallera DA; Ettestad B; Hallstrom C; Kodal B; Todhunter DA; Bendzick L; Hinderlie P; Walker JT; Pulkrabek B; Pastan I; Kratzke RA; Fujioka N; Miller JS; Felices M
Front Immunol; 2023; 14():1060905. PubMed ID: 36911670
[TBL] [Abstract][Full Text] [Related]
3. Natural Killer Cells: The Linchpin for Successful Cancer Immunotherapy.
Shaver KA; Croom-Perez TJ; Copik AJ
Front Immunol; 2021; 12():679117. PubMed ID: 33995422
[TBL] [Abstract][Full Text] [Related]
4. Natural killer cell‑based immunotherapy for lung cancer: Challenges and perspectives (Review).
Zeng Y; Lv X; Du J
Oncol Rep; 2021 Nov; 46(5):. PubMed ID: 34498710
[TBL] [Abstract][Full Text] [Related]
5. IL-15 superagonist RLI has potent immunostimulatory properties on NK cells: implications for antimetastatic treatment.
Desbois M; Béal C; Charrier M; Besse B; Meurice G; Cagnard N; Jacques Y; Béchard D; Cassard L; Chaput N
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32532840
[TBL] [Abstract][Full Text] [Related]
6. Host-Related Factors as Targetable Drivers of Immunotherapy Response in Non-Small Cell Lung Cancer Patients.
Baci D; Cekani E; Imperatori A; Ribatti D; Mortara L
Front Immunol; 2022; 13():914890. PubMed ID: 35874749
[TBL] [Abstract][Full Text] [Related]
7. Natural killer cells in the human lung tumor microenvironment display immune inhibitory functions.
Russick J; Joubert PE; Gillard-Bocquet M; Torset C; Meylan M; Petitprez F; Dragon-Durey MA; Marmier S; Varthaman A; Josseaume N; Germain C; Goc J; Dieu-Nosjean MC; Validire P; Fournel L; Zitvogel L; Bindea G; Lupo A; Damotte D; Alifano M; Cremer I
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33067317
[TBL] [Abstract][Full Text] [Related]
8. Harnessing Natural Killer Immunity in Metastatic SCLC.
Best SA; Hess JB; Souza-Fonseca-Guimaraes F; Cursons J; Kersbergen A; Dong X; Rautela J; Hyslop SR; Ritchie ME; Davis MJ; Leong TL; Irving L; Steinfort D; Huntington ND; Sutherland KD
J Thorac Oncol; 2020 Sep; 15(9):1507-1521. PubMed ID: 32470639
[TBL] [Abstract][Full Text] [Related]
9. Grain-sized moxibustion promotes NK cell antitumour immunity by inhibiting adrenergic signalling in non-small cell lung cancer.
Hu D; Shen W; Gong C; Fang C; Yao C; Zhu X; Wang L; Zhao C; Zhu S
J Cell Mol Med; 2021 Mar; 25(6):2900-2908. PubMed ID: 33506637
[TBL] [Abstract][Full Text] [Related]
10. NK cell-based therapeutics for lung cancer.
Pockley AG; Vaupel P; Multhoff G
Expert Opin Biol Ther; 2020 Jan; 20(1):23-33. PubMed ID: 31714156
[No Abstract] [Full Text] [Related]
11. Natural Killer Cells and Dendritic Cells: Expanding Clinical Relevance in the Non-Small Cell Lung Cancer (NSCLC) Tumor Microenvironment.
Ahluwalia P; Ahluwalia M; Mondal AK; Sahajpal NS; Kota V; Rojiani MV; Kolhe R
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439191
[TBL] [Abstract][Full Text] [Related]
12. Natural Killer Cells as a Potential Biomarker for Predicting Immunotherapy Efficacy in Patients with Non-Small Cell Lung Cancer.
Cho YH; Choi MG; Kim DH; Choi YJ; Kim SY; Sung KJ; Lee JC; Kim SY; Rho JK; Choi CM
Target Oncol; 2020 Apr; 15(2):241-247. PubMed ID: 32285316
[TBL] [Abstract][Full Text] [Related]
13. Harnessing the Potential of NK Cell-Based Immunotherapies against Multiple Myeloma.
Reina-Ortiz C; Giraldos D; Azaceta G; Palomera L; Marzo I; Naval J; Villalba M; Anel A
Cells; 2022 Jan; 11(3):. PubMed ID: 35159200
[TBL] [Abstract][Full Text] [Related]
14. The proangiogenic phenotype of natural killer cells in patients with non-small cell lung cancer.
Bruno A; Focaccetti C; Pagani A; Imperatori AS; Spagnoletti M; Rotolo N; Cantelmo AR; Franzi F; Capella C; Ferlazzo G; Mortara L; Albini A; Noonan DM
Neoplasia; 2013 Feb; 15(2):133-42. PubMed ID: 23441128
[TBL] [Abstract][Full Text] [Related]
15. CCR4 mediated chemotaxis of regulatory T cells suppress the activation of T cells and NK cells via TGF-β pathway in human non-small cell lung cancer.
Liu W; Wei X; Li L; Wu X; Yan J; Yang H; Song F
Biochem Biophys Res Commun; 2017 Jun; 488(1):196-203. PubMed ID: 28487109
[TBL] [Abstract][Full Text] [Related]
16. Immune Cell Composition in Human Non-small Cell Lung Cancer.
Stankovic B; Bjørhovde HAK; Skarshaug R; Aamodt H; Frafjord A; Müller E; Hammarström C; Beraki K; Bækkevold ES; Woldbæk PR; Helland Å; Brustugun OT; Øynebråten I; Corthay A
Front Immunol; 2018; 9():3101. PubMed ID: 30774636
[TBL] [Abstract][Full Text] [Related]
17. Potential value of efficacy prediction and treatment of natural killer cells in extensive stage small cell lung cancer.
Cui Y; Zhao P; Cheng Y; Ren X
Thorac Cancer; 2023 Apr; 14(10):864-872. PubMed ID: 36861174
[TBL] [Abstract][Full Text] [Related]
18. Natural killer cells: the next wave in cancer immunotherapy.
Chen X; Jiang L; Liu X
Front Immunol; 2022; 13():954804. PubMed ID: 35967421
[TBL] [Abstract][Full Text] [Related]
19. Tumor intrinsic and extrinsic functions of CD73 and the adenosine pathway in lung cancer.
Kowash RR; Akbay EA
Front Immunol; 2023; 14():1130358. PubMed ID: 37033953
[TBL] [Abstract][Full Text] [Related]
20. Impaired zeta chain expression and IFN-gamma production in peripheral blood T and NK cells of patients with advanced lung cancer.
Ciszak L; Kosmaczewska A; Werynska B; Szteblich A; Jankowska R; Frydecka I
Oncol Rep; 2009 Jan; 21(1):173-84. PubMed ID: 19082459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
